Dowler S, et al. (2000) Phosphoinositide 3-kinase-dependent phosphorylation of the dual adaptor for phosphotyrosine and 3-phosphoinositides by the Src family of tyrosine kinase. Biochem J 349, 605-10 10880360

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y139-p - DAPP1 (human) ▲

Modsite: kVEEPsIyEsVRVHT SwissProt Entrez-Gene Orthologous residues DAPP1 (human): Y139‑p, DAPP1 iso2 (human): Y139‑p, DAPP1 (mouse): Y139‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE LYN (human) KINASE Src (human) KINASE Lck (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE Src (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme, phospho-motif antibody Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin increase wortmannin insulin inhibit treatment-induced increase LY294002 insulin inhibit treatment-induced increase PP2 insulin inhibit treatment-induced increase PP3 insulin no effect upon treatment-induced increase IGF-1 increase wortmannin IGF-1 inhibit treatment-induced increase LY294002 IGF-1 inhibit treatment-induced increase IGF-1 PIK3R1 (human) inhibit treatment-induced increase dominant negative PP2 IGF-1 inhibit treatment-induced increase EGF increase wortmannin EGF inhibit treatment-induced increase LY294002 EGF inhibit treatment-induced increase PP2 EGF inhibit treatment-induced increase PIK3CD (human) increase constitutively active LYN (human) increase Lck (human) increase